TY - JOUR
T1 - Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients
T2 - a systematic review and meta-analysis
AU - Badreddine, J.
AU - Lee, M. H.
AU - Mishra, K.
AU - Pope, R.
AU - Kim, J. Y.
AU - Hong, S. H.
AU - Gupta, S.
AU - Song, J. M.
AU - Shin, Jae Il
AU - Ghayda, R. A.
N1 - Funding Information:
No financial support was provided for research conduct and/ or preparation of the article.
Publisher Copyright:
© 2022 Verduci Editore s.r.l. All rights reserved.
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: The aim of this study is to compare the risk of venous thromboembolic events (VTE) between patients suspending and continuing estrogen therapy perioperatively, in male to female gender-affirming surgery (vaginoplasty). MATERIALS AND METHODS: The authors conducted a systematic review and meta-analysis of existing research on male to female gender-affirming study, which compared the risk of VTE among the usage of estrogen perioperatively. RESULTS: A total of 209 studies were identified as potentially eligible among PubMed, Embase, and Cochrane library databases. Among the studies, 191 studies were excluded due to their abstract inappropriateness. Out of the remaining 18 studies, only 3 articles were eligible and were finally included. Meta-analysis was performed and showed odds ratio of 0.77 (95% CI: 0.04, 14.01). CONCLUSIONS: Perioperative estrogen therapy does not increase VTE risk on male to female gender-affirming surgery. Therefore, estrogen therapy may be continued perioperatively in vaginoplasty. More prospective studies are needed.
AB - OBJECTIVE: The aim of this study is to compare the risk of venous thromboembolic events (VTE) between patients suspending and continuing estrogen therapy perioperatively, in male to female gender-affirming surgery (vaginoplasty). MATERIALS AND METHODS: The authors conducted a systematic review and meta-analysis of existing research on male to female gender-affirming study, which compared the risk of VTE among the usage of estrogen perioperatively. RESULTS: A total of 209 studies were identified as potentially eligible among PubMed, Embase, and Cochrane library databases. Among the studies, 191 studies were excluded due to their abstract inappropriateness. Out of the remaining 18 studies, only 3 articles were eligible and were finally included. Meta-analysis was performed and showed odds ratio of 0.77 (95% CI: 0.04, 14.01). CONCLUSIONS: Perioperative estrogen therapy does not increase VTE risk on male to female gender-affirming surgery. Therefore, estrogen therapy may be continued perioperatively in vaginoplasty. More prospective studies are needed.
UR - http://www.scopus.com/inward/record.url?scp=85128795674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128795674&partnerID=8YFLogxK
U2 - 10.26355/eurrev_202204_28488
DO - 10.26355/eurrev_202204_28488
M3 - Article
C2 - 35442466
AN - SCOPUS:85128795674
SN - 1128-3602
VL - 26
SP - 2511
EP - 2517
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 7
ER -